https://hipa.ai/drug/pembrolizumab/updates/trial-results-posted-nct05714553-2026-07-23 Hipa.ai en 2026-07-23T00:00:00.000Z Pembrolizumab Combination Shows Objective Response in Advanced Solid Tumors https://hipa.ai/drug/guselkumab/updates/trial-results-posted-nct05071664-2026-07-23 Hipa.ai en 2026-07-23T00:00:00.000Z Guselkumab Plus Golimumab Improves Psoriatic Arthritis ACR 50 Response https://hipa.ai/drug/sotorasib/updates/trial-results-posted-nct05198934-2026-07-22 Hipa.ai en 2026-07-22T00:00:00.000Z Sotorasib + Panitumumab Improves PFS in KRAS G12C Colorectal Cancer https://hipa.ai/drug/pembrolizumab/updates/trial-results-posted-nct05167409-2026-07-22 Hipa.ai en 2026-07-22T00:00:00.000Z Pembrolizumab Combo Trial for mCRC Terminated, Shows Limited Response https://hipa.ai/drug/atezolizumab/updates/trial-results-posted-nct04776447-2026-07-22 Hipa.ai en 2026-07-22T00:00:00.000Z Atezolizumab Plus Chemotherapy Shows 68.4% 12-Month PFS in Stage IIIA/IIIB NSCLC https://hipa.ai/drug/tofacitinib/updates/boxed-warning-present-label-tofacitinib-citrate-label-2026-07-21 Hipa.ai en 2026-07-21T00:00:00.000Z Tofacitinib (Xeljanz) Label Adds Boxed Warning for Infections, Mortality https://hipa.ai/drug/pembrolizumab/updates/trial-results-posted-nct04949256-2026-07-20 Hipa.ai en 2026-07-20T00:00:00.000Z Keytruda + Lenvatinib + Chemo Improves ORR in Metastatic Esophageal Carcinoma https://hipa.ai/drug/orforglipron/updates/trial-results-posted-nct05931380-2026-07-20 Hipa.ai en 2026-07-20T00:00:00.000Z Orforglipron Shows Significant Weight Loss in Japanese Adults with Obesity https://hipa.ai/drug/canagliflozin/updates/boxed-warning-revised-metformin-hydrochloride-label-2026-07-20 Hipa.ai en 2026-07-20T00:00:00.000Z Metformin Hydrochloride Boxed Warning Revised on Lactic Acidosis Risk